サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625024

次世代シーケンシング（NGS）サービス市場：技術、用途、エンドユーザー、サービスタイプ、地域別、2024年～2031年

Next-Generation Sequencing Services Market By Technology, Application, End-User (Hospitals and Clinics, Contract Research Organizations ), Service Type, & Region for 2024-2031

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
次世代シーケンシング（NGS）サービス市場：技術、用途、エンドユーザー、サービスタイプ、地域別、2024年～2031年
出版日: 2024年08月27日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

次世代シーケンシング（NGS）サービスの市場評価-2024年～2031年

次世代シーケンシング（NGS）サービスに対する需要の高まりは、個別化医療と診断に対する破壊的な影響によるところが大きいです。NGSは、特に腫瘍学、遺伝性疾患、感染症などにおいて、ヘルスケアプロバイダーが疾患診断と治療にアプローチする方法を一変させました。NGSは、全ゲノムまたは選択された領域の迅速かつ信頼性の高いシーケンシングを可能にすることで、標的医薬品に情報を提供できる遺伝子変化の検出を可能にし、その結果、市場は2024年に95億3,000万米ドルの収益を突破し、2031年には約183億5,000万米ドルの評価に達することで、患者の転帰を改善します。

予防ヘルスケア重視の高まりがNGSサービスの需要を押し上げています。ヘルスケアシステムが疾病の発見と予防に向かう中、NGSは包括的なゲノム・スクリーニングを提供し、特定の疾病に対する素因を特定し、早期介入を可能にします。これは薬理ゲノミクスの分野で特に重要であり、NGSは個人が特定の医薬品にどのように反応するかを予測するために使用されるため、2024年から2031年にかけて21.25%のCAGRで市場が成長することを可能にすることで、悪い薬物反応を減らすことができます。

次世代シーケンシング（NGS）サービス市場：定義/概要

次世代シーケンシング（NGS）サービスは、DNAまたはRNAの迅速なシーケンシングを可能にし、遺伝子情報を大規模に評価する先進のゲノム技術です。NGSサービスは、医学研究や診断、創薬、個別化医療など幅広い用途で必要とされる、遺伝子変異、突然変異、遺伝子発現に関する重要な洞察を与えます。

次世代シーケンシング（NGS）サービスには、遺伝学、医療診断、オーダーメイド医療など数多くの用途があります。最も一般的な用途の1つは遺伝学的検査で、遺伝性の遺伝子異常、変異、疾患傾向を特定します。NGSは、ゲノム全体または特定の領域の迅速かつハイスループットなシーケンスを可能にし、がん、嚢胞性線維症、心血管疾患などの疾患の原因となる遺伝子変異に関する広範な情報を明らかにします。

次世代シーケンシング（NGS）サービスの今後の利用は、個別化医療やゲノミクスを含むヘルスケアの多くの側面を変革すると期待されています。最も有望なアプリケーションの1つはがんの診断と治療で、NGSは詳細な腫瘍プロファイリングを提供し、がん増殖の原因となる特定の遺伝子異常を突き止める可能性があります。

次世代シーケンシング（NGS）サービス市場の普及を促進する主な要因は何ですか？

次世代シーケンシング（NGS）サービスの利用は、主に個別化医療におけるアプリケーションの増加、ゲノム研究の進歩、およびシーケンシング技術コストの低下によって後押しされています。これらの特徴が、ヘルスケアおよびライフサイエンスのさまざまな用途におけるNGSの利用を促進しています。個別化医療はNGSサービス普及の主な推進力です。米国食品医薬品局（FDA）によると、2022年現在、過去5年間に承認された新医薬品の25％以上が個別化医療で、その多くはNGS技術を用いて開発されたものです。

米国国立ヒトゲノム研究所（NHGRI）によると、ヒトゲノムの塩基配列決定にかかるコストは、2001年の約1億米ドルから2022年には1,000米ドル以下と、10万分の1にまで低下しています。もうひとつの重要な要因は、がん研究と治療におけるNGSの応用が拡大していることです。米国国立がん研究所のがんゲノムアトラス（TCGA）は、33のがん種から採取した2万以上の原発性がんとそれに適合する正常サンプルを評価するためにNGS技術を使用しました。腫瘍学におけるこのような広範な応用は、NGSサービス業界を前進させています。

倫理的および法的な懸念は次世代シーケンシング（NGS）サービス市場の妨げになるか？

倫理的および法的な考慮事項は、次世代シーケンシング（NGS）サービス分野の拡大に大きな影響を与えます。主な倫理的考慮事項の1つは、プライバシーと遺伝子データの取り扱いです。NGSサービスにはヒトゲノムのシーケンシングが含まれるため、適切に保護されなければ悪用される可能性のあるセンシティブな個人情報が生成されます。遺伝子データへの無許可のアクセスは、雇用や保険における遺伝的差別などの悪用に関する問題を引き起こします。

法的問題もNGSサービス事業にとって、特に規制遵守や知的財産権の面でハードルとなります。NGS技術の進歩に伴い、ゲノム情報の利用を管理する法的枠組みは進化し続けています。国によって政策に一貫性がないため、国際的な共同研究が妨げられ、市場の成長が制限されます。企業は複雑な特許規制、特にゲノム配列とNGS関連技術の所有権に関する規制を管理しなければならないです。さらに、ヒト遺伝子や特定のゲノム配列の特許をめぐる法廷闘争は、技術革新を阻害し、重要なNGSサービスへのアクセスを制限する可能性があります。

目次

第1章 次世代シーケンシング（NGS）サービスの世界市場：イントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査スケジュール
  • 前提条件
  • 制限事項

第2章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • データの三角測量
  • ボトムアップアプローチ
  • トップダウンアプローチ
  • 調査の流れ
  • 業界専門家による主要な洞察
  • データソース

第3章 エグゼクティブサマリー

  • 市場概要
  • エコロジーのマッピング
  • 絶対的収益機会
  • 市場の魅力
  • 次世代シーケンシング（NGS）サービスの世界市場：地域別分析（CAGR）
  • 次世代シーケンシング（NGS）サービスの世界市場：サービスタイプ別
  • 次世代シーケンシング（NGS）サービスの世界市場：技術別
  • 次世代シーケンシング（NGS）サービスの世界市場：エンドユーザー別
  • 次世代シーケンシング（NGS）サービスの世界市場：用途別
  • 今後の市場機会
  • 世界市場内訳
  • 製品ライフライン

第4章 次世代シーケンシング（NGS）サービスの世界市場展望

  • 世界の次世代シーケンシング（NGS）サービスの進化
  • 促進要因
  • 抑制要因
  • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 価格分析
  • マクロ経済分析

第5章 次世代シーケンシング（NGS）サービスの世界市場：サービスタイプ別

  • 概要
  • エクソームシーケンス
  • ターゲットリシーケンスおよびカスタム遺伝子パネル
  • 全ゲノムシーケンス＆デノボシーケンス、RNA-Seq
  • その他

第6章 次世代シーケンシング（NGS）サービスの世界市場：技術別

  • 概要
  • 合成によるシーケンシング
  • イオン半導体シーケンシング
  • 単分子リアルタイムシーケンシング
  • ナノポアシーケンシング

第7章 次世代シーケンシング（NGS）サービスの世界市場：エンドユーザー別

  • 概要
  • 学術機関および政府機関、研究センター
  • 病院・クリニック
  • 製薬・バイオテクノロジー企業
  • その他

第8章 次世代シーケンシング（NGS）サービスの世界市場：用途別

  • 概要
  • 診断
  • 創薬
  • バイオマーカー探索
  • 農業・動物研究
  • その他

第9章 次世代シーケンシング（NGS）サービスの世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第10章 次世代シーケンシング（NGS）サービスの世界市場：競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な発展
  • 企業の地域別フットプリント
  • 企業の業界フットプリント
  • ACEマトリックス

第11章 企業プロファイル

  • Eurofins Scientific
  • illumina, Inc.
  • BGI genomics Co., Ltd.
  • Perkinelmer Inc.
  • Macrogen, Inc.
  • Qiagen N.V.
  • Genewiz
  • Personalis, Inc.
  • Takara Bio Inc.
  • LGC Science Group Holdings Limited

第12章 VERIFIED MARKET RESEARCH

  • VERIFIED MARKET RESEARCHについて
  • ダイナミックなデータの可視化
目次
Product Code: 25919

Next-Generation Sequencing (NGS) Services Market Valuation - 2024-2031

The growing demand for next-generation sequencing (NGS) services is largely due to its disruptive impact on personalized medicine and diagnostics. NGS has transformed how healthcare providers approach disease diagnosis and therapy, especially in oncology, genetic disorders, and infectious diseases. NGS enables the speedy and reliable sequencing of complete genomes or select areas allowing the detection of genetic alterations that can inform targeted medicines, hence improving patient outcomes by enabling the market to surpass a revenue of USD 9.53 Billion valued in 2024 and reach a valuation of aroundUSD 18.35 Billion by 2031.

The increased emphasis on preventative healthcare is driving up the demand for NGS services. As healthcare systems turn toward disease detection and prevention, NGS provides comprehensive genomic screening, identifying predispositions to specific ailments and allowing for earlier interventions. This is especially crucial in the field of pharmacogenomics where NGS is used to anticipate how individuals will react to specific pharmaceuticals, hence reducing bad drug responses by enabling the market to grow at aCAGR of 21.25% from 2024 to 2031.

Next Generation Sequencing (NGS) Services Market: Definition/ Overview

Next Generation Sequencing (NGS) services are advanced genomic technologies that enable quick sequencing of DNA or RNA to evaluate genetic information on a massive scale. NGS services give critical insights into genetic variants, mutations, and gene expression which are required for a wide range of applications including medical research and diagnostics, drug discovery, and personalized medicine.

Next Generation Sequencing (NGS) services have numerous uses including genetics, medical diagnostics, and customized medicine. One of the most common applications is genetic testing, which identifies inherited genetic abnormalities, mutations, and disease propensity. NGS enables quick, high-throughput sequencing of entire genomes or particular areas revealing extensive information about genetic variants that contribute to disorders including cancer, cystic fibrosis, and cardiovascular disease.

The future usage of next-generation sequencing (NGS) services is expected to transform numerous aspects of healthcare including personalized medicine and genomics. One of the most promising applications is cancer diagnosis and treatment where NGS may give detailed tumor profiling and pinpoint particular genetic abnormalities that cause cancer growth.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers Promoting the Adoption of the Next-Generation Sequencing (NGS) Services Market?

The use of next-generation sequencing (NGS) services is being pushed primarily by increased applications in personalized medicine, advances in genomic research, and lower sequencing technology costs. These characteristics are driving the usage of NGS in a variety of healthcare and life sciences applications. Personalized medicine is a primary driver of NGS service uptake. According to the U.S. Food and Drug Administration (FDA), as of 2022, more than 25% of new pharmaceuticals approved in the past five years were personalized medicines many of which were developed using NGS technologies.

According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has dropped from approximately USD 100 Million in 2001 to less than $1,000 in 2022, a 100,000-fold decrease. Another key factor is the growing application of NGS in cancer research and treatment. The National Cancer Institute's Cancer Genome Atlas (TCGA) used NGS technology to evaluate over 20,000 primary cancers and matched normal samples from 33 cancer types. This widespread application in oncology is driving the NGS services industry forward.

Will the Ethical and Juridical Concerns Hamper the Next Generation Sequencing (NGS) Services Market?

Ethical and legal considerations have a substantial impact on the expansion of the next generation sequencing (NGS) services sector. One of the main ethical considerations is privacy and the handling of genetic data. Because NGS services include the sequencing of human genomes, sensitive personal information is generated which could be misused if not appropriately protected. Unauthorized access to genetic data raises issues about misuse such as genetic discrimination in employment or insurance.

Legal problems also pose hurdles for the NGS services business, particularly in terms of regulatory compliance and intellectual property rights. As NGS technology progresses, the legal framework governing genomic information use continues to evolve. Inconsistent policies across countries hamper international collaborations and limit market growth. Companies must manage complex patent regulations, particularly those governing ownership of genomic sequences and NGS-related technologies. Furthermore, legal battles over the patenting of human genes or specific genomic sequences can stifle innovation and restrict access to critical NGS services.

Category-Wise Acumens

How Will the Increasing Popularity of Whole Genome Sequencing Drive the Adoption of Next-Generation Sequencing (NGS) Services?

Whole genome sequencing (WGS) is a dominating technology in the next-generation sequencing (NGS) services industry due to its comprehensive nature and wide range of applications across industries. The ability to study genetic variations, mutations, structural changes, and functional elements across the entire genome providing insights into complex biological processes, disease mechanisms, and personalized medicine applications is increasing the use of WGS by researchers, clinicians, and organizations.

In addition, its involvement in discovering novel genetic markers, biomarkers, disease-causing mutations, and therapeutic targets for expanding our understanding of genetic features, hereditary diseases, complex disorders, and genetic predispositions will further accelerate the usage of WGS. In clinical diagnostics and healthcare, WGS is critical for genetic testing, illness diagnosis, and tailored medication. This allows clinicians to identify disease-causing mutations, analyze genetic risk factors, diagnose uncommon genetic illnesses, predict therapy responses, and adapt medicines to individual genomic profiles.

In What Ways are Hospitals and Clinics Driving the Growth of the Next-Generation Sequencing (NGS) Services Market?

The increase in demand for NGS services in hospitals and clinics for a wide range of clinical diagnostic applications including prenatal screening, pharmacogenomics, cancer genomics, rare illness detection, and infectious disease testing is a market profitable factor. NGS enables clinicians to perform the necessity for doctors to conduct complete genomic profiling of patient samples and find genetic mutations, structural variants, and biomarkers to provide accurate prognosis, treatment response, and disease risk data is expected to drive market expansion.

By incorporating genomic information into clinical decision-making, hospitals and clinics can improve treatment outcomes, reduce adverse medication responses, and increase patient happiness and quality of life. Genomic medicine research is widely conducted at hospitals and university medical institutes to improve scientific understanding of hereditary illnesses, molecular pathways, and therapeutic targets. NGS services contribute significantly to genomic research projects by facilitating large-scale DNA sequencing, genome-wide association studies (GWAS), and functional genomics experiments.

Country/Region-wise Acumens

Will the Development of Precision and Tailored Treatments Drive the Market in the North American Region?

North America dominates the next generation sequencing (NGS) services market owing to its advanced healthcare infrastructure and major investments in precision medicine. The Precision Medicine Initiative, initiated by the US government in 2015 with an initial USD 215 Million commitment, has been a significant driver of NGS uptake. The National Institutes of Health's (NIH) "All of Us" Research Program, which is part of this project, seeks to collect genetic data from one million Americans and has already registered over 500,000 people as of 2023.

The NIH's Undiagnosed Diseases Network has employed NGS to diagnose 35% of cases, demonstrating the technology's utility. Furthermore, the Centers for Medicare & Medicaid Services (CMS) enhanced coverage for NGS-based diagnostic tests for individuals with hereditary ovarian or breast cancer in 2020, possibly benefiting up to 100,000 Medicare patients per year. This coverage expansion is projected to dramatically increase the use of NGS services in clinical settings. According to the Centers for Disease Control and Prevention (CDC), more than 1.8 million SARS-CoV-2 genomes will have been sequenced in the United States by 2022, demonstrating the importance of NGS in disease surveillance and pandemic response.

Will the Increasing Demand for Genomic Therapeutics and Whole-Genome Sequencing Drive the Market in the Asia Pacific Region?

The Asia Pacific region is seeing the highest growth in the next generation sequencing (NGS) services market owing to increased demand for genomic therapies and whole-genome sequencing. Significant government funding, increased research activity, and the region's expanding prevalence of genetic illnesses all contribute to its rapid growth. This investment has already paid off with the number of whole-genome sequencing studies in China increasing by 120% between 2015 and 2020, according to the National Center for Biotechnology Information (NCBI).

Another important factor is the region's rising prevalence of genetic diseases. According to the World Health Organization (WHO), the incidence of genetic disorders in Asia is 53.5 per 1,000 live births which is higher than the global average of 39.7. This has resulted in an increased demand for genetic testing and tailored medicine. Since 2017, the South Korean government's Genome Technology to Business Translation Program has invested USD 70 Million in 100 genomics-based startups. Australia's Genomes Health Futures Mission which is part of the Medical Research Future Fund has committed AU$500 million over ten years to genomes research, with AU$150 million already funded by 2023.

Competitive Landscape

The Next Generation Sequencing (NGS) Services Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the next-generation sequencing (NGS) services market include:

Quest Diagnostics Incorporated

ARUP Laboratories

Applied Biological Materials, Inc.

Novogene Co, Ltd.

Azenta Life Sciences (GENEWIZ)

NanoString

Illumina, Inc.

PacBio

Veritas

BGI (Beijing Genomics Institute)

Gene by Gene Ltd.

Lucigen Corporation

Latest Developments

In August 2022, A market leader in clinical diagnostics and life science research introduced a line of type 1 antibodies that prevent the drug evolocumab (Repatha(R)) from binding to its intended target, the human proprotein convertase subtilisin/Kexin type 9 (PCSK9), which has been linked to cholesterol control. These recombinant antibodies with predetermined sequences can be employed to develop highly sensitive and selective evolocumab and biosimilar-specific pharmacokinetic (PK) and anti-drug antibody (ADA) assays.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Next-Generation Sequencing (NGS) Services Market Geographical Analysis (CAGR %)
  • 3.6 Global Next-Generation Sequencing (NGS) Services Market, By Service Type (USD Million)
  • 3.7 Global Next-Generation Sequencing (NGS) Services Market, By Technology (USD Million)
  • 3.8 Global Next-Generation Sequencing (NGS) Services Market, By End-Users (USD Million)
  • 3.9 Global Next-Generation Sequencing (NGS) Services Market, By Application (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET OUTLOOK

  • 4.1 Global Next-Generation Sequencing (NGS) Services Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY SERVICE TYPE

  • 5.1 Overview
  • 5.2 Exome Sequencing
  • 5.3 Targeted Resequencing & Custom Gene Panels
  • 5.4 Whole-Genome Sequencing & De Novo Sequencing, RNA-Seq
  • 5.5 Others

6 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Sequencing By Synthesis
  • 6.3 Ion Semiconductor Sequencing
  • 6.4 Single-Molecule Real-Time Sequencing
  • 6.5 Nanopore Sequencing

7 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY END-USERS

  • 7.1 Overview
  • 7.2 Academic & Government Institutes and Research Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Pharmaceutical & Biotechnology Companies
  • 7.5 Others

8 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Diagnostics
  • 8.3 Drug Discovery
  • 8.4 Biomarker Discovery
  • 8.5 Agriculture & Animal Research
  • 8.6 Others

9 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle-East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Eurofins Scientific
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Development
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.2 illumina, Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.3 BGI genomics Co., Ltd.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Perkinelmer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Development
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Macrogen, Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Development
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Qiagen N.V.
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Development
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Genewiz
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Development
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Personalis, Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Development
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Takara Bio Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Development
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 LGC Science Group Holdings Limited
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Development
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET RESEARCH

  • 12.1 About Verified Market Research
  • 12.2 Dynamic Data Visualization